A framework to determine when liver transplantation is futile
AASLD LiverLearning®, Jennifer Lai, 165947
The changing face of hepatic encephalopathy: A projection for the next 5 years
AASLD LiverLearning®, Debbie L Shawcross, 165948
Treatment of chronic cholestasis: What we know and what we will know?
AASLD LiverLearning®, James Boyer, 165949
Managing encephalopathy in the outpatient setting
AASLD LiverLearning®, Radha Dhiman, 165950
Mechanisms of portal hypertension: Bench to bedside
AASLD LiverLearning®, Jordi Gracia‐Sancho, 165951
Novel approaches to the treatment of biliary atresia
AASLD LiverLearning®, Jorge A. Bezerra, 165952
Novel treatments targeting immune‐related mechanisms in primary biliary cholangitis
AASLD LiverLearning®, Pietro Invernizzi, 164849
How does the microbiome affect liver disease?
AASLD LiverLearning®, Herbert Tilg, 164850
Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma
AASLD LiverLearning®, Ali Canbay, 164851
The scope of hepatology practice outside the traditional academic medical center
AASLD LiverLearning®, Marcelo Kugelmas, 164852
Novel treatments in primary sclerosing cholangitis
AASLD LiverLearning®, Keith Lindor, 164853
Cystic Fibrosis–Related Liver Diseases: New Paradigm for Treatment Based on Pathophysiology
AASLD LiverLearning®, Mario Strazzabosco, 164854
Clinical Hepatology Debrief
AASLD LiverLearning®, Arun Sanyal, 154738
Elimination of Hepatitis B: Is It possible?
AASLD LiverLearning®, Anna Lok, 154737
Hepatitis Debrief
AASLD LiverLearning®, Robert Brown, 154735
Pangenotypic Regimens and the Next Generation of HCV Treatment
AASLD LiverLearning®, Nancy Reau, 154728
Resistance Testing: Interpretation and Incorporation into Treatment Algorithms
AASLD LiverLearning®, Jordan Feld, 154727
Management of Acute Variceal Bleed
AASLD LiverLearning®, Shiv Kumar Sarin, 154734
Treatment of Persons Who Inject Drugs (PWID): Treatment as Prevention
AASLD LiverLearning®, Jason Grebely, 154726
Non-cirrhotic Portal Hypertension: Eastern Perspective
AASLD LiverLearning®, Hitoshi Maruyama, 154733
In memoriam: Maribel Rodrigez Torres
AASLD LiverLearning®, Norbert Brau, 155710
HCV Symposium: Challenges in the DAA Era: Program Chair
AASLD LiverLearning®, Norah Terrault, 154723
Patients with Renal Failure: When and How to Treat?
AASLD LiverLearning®, David Roth, 154725
TIPS: Is Early Intervention Helpful?
AASLD LiverLearning®, Florence Wong, 154732
Non-cirrhotic Portal Hypertension: Western Perspective
AASLD LiverLearning®, Theo Heller, 154731
AASLD-APASL Symposium: Portal Hypertension: Program Chair
AASLD LiverLearning®, Rajender Reddy, 154729
New Treatments for NASH
AASLD LiverLearning®, Brent Tetri, 154722
Advances in Non-invasive Assessment and Genetics of NAFLD
AASLD LiverLearning®, Christopher Paul Day, 154721
Advances in the Management of Alcoholic Liver Disease
AASLD LiverLearning®, Philippe MATHURIN, 154720
Mental Health Predictors of All Oral Direct Acting Antiviral Receipt in Individuals with Hepatitis C Virus Infection
AASLD LiverLearning®, Jennifer Kramer, 144643
Risk Factors Associated with Colonization or Infection with a Multi-Drug Resistant Organism in Patients with Cirrhosis
AASLD LiverLearning®, Monica Schmidt, 144644
Geographic Disparities in Incidence and All Cause Mortality Among Patients with Hepatocellular Carcinoma
AASLD LiverLearning®, Ricardo Franco, 144645
Real-life Hepatitis C treatment: effectiveness of 8 or 12 week Sofosbuvir/Ledipasvir in Genotype 1 non-cirrhotic treatment-naive mono or HIV-coinfected patients
Safety and Efficacy of Sofosbuvir in Combination with Daclatasvir or Simeprevir With or Without Ribavirin in the Treatment of Chronic HCV Genotype 4-infected Patients: A Real World Experience.
AASLD LiverLearning®, Ali Albenmousa, 144902
Eliminating Hepatitis C in Spain: Bridging from the National Health Plan
AASLD LiverLearning®, Maria Buti, 144659
Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis
AASLD LiverLearning®, David Goldberg, 144660
Alcohol use disorder among chronic hepatitis C patients: prevalence and treatment outcome, CHeCS, 2006-2013
AASLD LiverLearning®, Eyasu Teshale, 144661
Are office visits and laboratory data monitoring required for chronic hepatitis C genotype 1 patients treated with Sofosbuvir based regimens that do not include Ribavirin?
AASLD LiverLearning®, Apurva Modi, 144917
Efficacy and safety of direct acting antiviral(s) (DAA) containing regimens in the treatment of chronic hepatitis C (CHC) patients with genotype 3. A real life experience
AASLD LiverLearning®, John Koskinas, 144918
Increased risk of hepatocellular carcinoma in patients with low-level viremia than maintained virological remission in patients receiving entecavir monotherapy
AASLD LiverLearning®, jung hee kim, 144675
HDV RNA replication is associated with high HBsAg levels irrespective of HBV DNA and linked with severe liver damage and end-stage liver disease complications
AASLD LiverLearning®, Ivana Carey, 144676
Quantifying perinatal transmission of Hepatitis B viral quasispecies by tag linkage deep sequencing
AASLD LiverLearning®, XIUMEI CHI, 144677
Which Extra-hepatic Organ Fails First does not affect Mortality Rates in Cirrhotic Inpatients
AASLD LiverLearning®, Jasmohan S. Bajaj, 144933
Elevated Ferritin is Associated with Increased Mortality in Patients with Cirrhosis Admitted to Intensive Care Units
AASLD LiverLearning®, Christina Lindenmeyer, 144934
A Primary Care and Community-Based Hepatitis B Screening and Linkage-to-Care Program in New Jersey
AASLD LiverLearning®, Su Wang, 144691
Chronic hepatitis D is a greater risk factor for hepatocellular carcinoma development than chronic hepatitis B
AASLD LiverLearning®, Onur Keskin, 144692
A brief introduction to the community-based comprehensive management of Hepatitis B demonstration project in Jiangsu province, china
AASLD LiverLearning®, Xiangjun Zhai, 144693
Novel Serum Biomarkers Predict Outcome in Compensated Cirrhosis
AASLD LiverLearning®, Audrey Dillon, 144949
Predicting Mortality in Patients with Cirrhosis Admitted to Intensive Care Units: A Novel Prognostic Model
AASLD LiverLearning®, Christina Lindenmeyer, 144950
Development of Hepatocellular Carcinoma after Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B
AASLD LiverLearning®, Sun Hong Yoo, 144708
Impact of FIB-4 index on HCC incidence during nucleos(t)ide analogue therapy in chronic hepatitis B patients: an analysis using time-dependent ROC
AASLD LiverLearning®, Toshifumi Tada, 144709
Pre-treatment and on-treatment predictors for the efficacy of tolvaptan in the treatment of refractory ascites due to cirrhosis
AASLD LiverLearning®, Yasuyuki Kommiyama, 144965
Targeted heart rate reduction using carvedilol± ivabradine improves left ventricular diastolic dysfunction, clinical progression and survival in cirrhosis
AASLD LiverLearning®, Madhumita Premkumar, 144966
Non-invasive prediction of liver disease in a multi-genotype cohort of hepatitis B e antigen negative patients
AASLD LiverLearning®, Gayatri Chakrabarty, 144724
Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir
AASLD LiverLearning®, Hiroki Nishikawa, 144725
Cirrhosis in hemodialyzed patients: time to decision is related to liver function
AASLD LiverLearning®, Florent Artru, 144981
Development of a novel staging model for cirrhosis outcome using the Nationwide Inpatient Sample
AASLD LiverLearning®, Mona Haj, 144982
Initial Follow Up Results from the REP 301 Trial: Safety and Efficacy of REP 2139-Ca and Pegylated Interferon Alpha-2a in Caucasian Patients with Chronic HBV / HDV Co-infection
AASLD LiverLearning®, Andrew Vaillant, 144740
LUNAR™-HBV, a UNA Oligomer Combination for the Treatment of Chronic Hepatitis B Virus Infection
AASLD LiverLearning®, Christine Esau, 144741
L-Isoleucine independently regulates protein synthesis and mitochondrial respiration in skeletal muscle cells during hyperammonemia
AASLD LiverLearning®, Srinivasan Dasarathy, 144997
Changes in Antimicrobial Susceptibility of Fecal Bacteria During Rifaximin Treatment for the Prevention of Overt Hepatic Encephalopathy (HE) Recurrence
AASLD LiverLearning®, Herbert DuPont, 144998
IFN-α-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection
AASLD LiverLearning®, Xiang-Yong Li, 144756
Development of Second Generation RNA Interference Therapy for Hepatitis B Virus Infection
AASLD LiverLearning®, Ammen Dhillon, 144757
Identification of novel CD8+ T-cell epitopes in HLA-A24-positive patients with hepatitis B virus.
AASLD LiverLearning®, Kiichiro Kaji, 144772
Safety, Tolerability and Pharmacokinetics of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Healthy Subjects.
AASLD LiverLearning®, Jeysen Yogaratnam, 144773
Fatigue & Hepatitis C: A Focus Group Study
AASLD LiverLearning®, Zobair Younossi, 144531
High HCV Cure Rates After Directly Acting Antivirals In Patients with Chronic Hepatitis C and Psychiatric Disorders
AASLD LiverLearning®, Anne Moore, 144532
Predictors of non-adherence to HBV anti-viral therapy
AASLD LiverLearning®, Suzanne Sheppard-Law, 144533
Blockage of HBV Virus Replication and Inhibition of cccDNA Establishment by Core Protein Allosteric Modifiers (CpAMs)
AASLD LiverLearning®, Qi Huang, 144789
Polyethylenimines (PEI) polymer functionalized with L-mannose moieties inhibits hepatitis B virus (HBV) entry into HepG2-hNTCP cells with negligible cellular toxicity.
AASLD LiverLearning®, Guan Huei Lee, 144790
The Role of Repeat Liver Biopsies in Autoimmune Hepatitis (AIH) at a Tertiary HPB Centre in South England, UK: Current experience, clinical dilemmas and recommendations
AASLD LiverLearning®, Claire Kelly, 144547
Autoimmune hepatitis: Impact of age at disease onset on disease severity, outcome and response to treatment.
AASLD LiverLearning®, Nikolaos Gatselis, 144548
Black and Latino Race/Ethnicity Increase the Risk of Hospitalization for Autoimmune Hepatitis in the United States
AASLD LiverLearning®, Jason Wen, 144549
The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
AASLD LiverLearning®, George Ioannou, 144805
Experience with Direct Antiviral Agents in Hispanic patients with Chronic Hepatitis C genotype 1 at the Veteran Affairs Caribbean Healthcare System in San Juan
AASLD LiverLearning®, Arnaldo L Freire-Perez, 144806
The role of Thy-1 in the pathogenesis of cholestatic liver fibrosis
AASLD LiverLearning®, Yukinori Koyama, 144563
TANGO1 mediates fibrogenesis in vivo and is regulated by the UPR
AASLD LiverLearning®, Jessica Maiers, 144564
The I148M PNPLA3 variant is a novel key player modulating the pro-fibrogenic phenotype of human hepatic stellate cells
AASLD LiverLearning®, Francesca Bruschi, 144565
The efficacy and safety of sofosbuvir plus ribavirin with or without peg-interferon in treatment of naïve and experienced Vietnamese patients with chronic genotype 1 and 6 HCV infection.
AASLD LiverLearning®, Thu Thuy Pham Thi, 144821
Efficacy and safety of DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort
AASLD LiverLearning®, Salvatore Madonia, 144822
Inhibition of vascular endothelial growth factor signaling facilitates recovery from acute ethanol-induced liver injury in zebrafish
AASLD LiverLearning®, Chunyue Yin, 144579
Profibrogenic properties of monoacylglycerol lipase in macrophages
AASLD LiverLearning®, Aida Habib, 144580
The Expression of MicroRNA-101 in Hepatic Cirrhosis - Hepatocellular Carcinoma and Its Effects on Hepatic Fibrosis
AASLD LiverLearning®, Chenghai Liu, 144581
Use of Ledipasvir/Sofosbuvir (LDV/SOF) with or without Ribavirin (RBV) in Genotype 1 (GT 1) HCV-infected Patients Post Liver Transplant (LT): Evaluation of Several Real-world Datasets (RWD)
AASLD LiverLearning®, Marc Bourliere, 144837
The Impact of Hepatitis C Virus Cure on Progression of Renal Disease
AASLD LiverLearning®, Carla Rodriguez, 144838
Combination therapy with mesenchymal stem cells and macrophages from bone marrow shows favorable outcome in mouse CCl4-induced liver cirrhosis model
AASLD LiverLearning®, Yusuke Watanabe, 144595
Frequency and Profile of decompensation in cirrhotics with Hepatic Venous Pressure Gradient below 10 mm Hg: Need to redefine CSPH
AASLD LiverLearning®, Ankit Bhardwaj, 144596
The Usefullness of WFA+-M2BP for predicting gastroesophageal varices and liver related events in HCV-related cirrhosis.
AASLD LiverLearning®, Tsuguru Hayashi, 144597
Hepatitis C Virus treatment outcomes in an inner-city population: 2004-2015
AASLD LiverLearning®, Vijay Dalapathi, 144853
The safety, tolerability and efficacy of paritaprevir/ritonavir/ombitasvir and dasabuvir with ribavirin in a large real life multi-center cohort of genotype 1b HCV infected patients with liver cirrhosis at the edge of decompensation
AASLD LiverLearning®, Ana Maria Singeap, 144854
Cost effectiveness analysis of potentially curative treatments for hepatocellular carcinoma with person-level data in a Canadian setting
AASLD LiverLearning®, Hla-Hla (Rosie) Thein, 144611
The Economic and Clinical Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the United States and Europe: A Steady-State Prevalence Model
AASLD LiverLearning®, Zobair Younossi, 144612
Cost and utility estimates for patients at different stages in the natural history of Primary Biliary Cirrhosis (PBC) from the UK-PBC Cohort
AASLD LiverLearning®, Stephen Rice, 144613
Effects of interferon-free treatment on serum cholesterol levels are different between the two sofosbuvir-based regimens in chronic HCV-infected patients
AASLD LiverLearning®, Naohiko Masaki, 144869
Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world.
AASLD LiverLearning®, Dost Sarpel, 144870
Potential Conflicts of Interest for Authors of Recent AASLD Clinical Practice Guidelines
AASLD LiverLearning®, Audrey Dillon, 144627
Comprehensive Liver Cancer Center Approach to Improve Treatment-Lag in Patients with Hepatocellular Carcinoma: A Tertiary Center Experience
AASLD LiverLearning®, Ramzi Mulki, 144628
Trends Comparing Alcohol Related Liver Disease in Women and Men in the United States from 2006 and 2013: A Nationwide Analysis
AASLD LiverLearning®, Lauren Stemboroski, 144629
Daclatasvir (DCV) plus Sofosbuvir (SOF) regimens in chronic Hepatitis C Virus (HCV) infected patients with advanced fibrosis or cirrhosis
AASLD LiverLearning®, Ioannis S Elefsiniotis, 144885
Effectiveness and safety of direct-acting antiviral therapies (DAA) in cirrhotic HCV monoinfected and HIV/HCV coinfected patient
AASLD LiverLearning®, Pilar Carmona, 144886